|
106 |
2024 Trends In FDA Observations For Sterile Drug Manufacturers
|
관리자 |
2025-02-28 |
226 |
|
105 |
Ensuring Repeatable, Viable Surface Sampling In Aseptic Settings
|
관리자 |
2025-02-28 |
221 |
|
104 |
Incubating settle plates: Understanding growth patterns and when things are going wrong
|
관리자 |
2025-02-03 |
394 |
|
103 |
11 Key Contributing Factors For Maintaining Sterility Assurance
|
관리자 |
2025-02-03 |
690 |
|
102 |
Physicochemical Monitoring of Pharmaceutical Water
|
관리자 |
2025-02-03 |
325 |
|
101 |
Audit Readiness For Cell & Gene Therapy Companies
|
관리자 |
2025-02-03 |
331 |
|
100 |
From missing Analysis to Brand Protection Violations - FDA Warning Letter to Canadian Manufacturer
|
sureAssist |
2025-01-02 |
368 |
|
99 |
Risk Analysis in Case of Insufficient Process Validation
|
sureAssist |
2025-01-02 |
362 |
|
98 |
Microbiological monitoring: Adapting to new rapid methods regulatory demands
|
sureAssist |
2025-01-02 |
315 |
|
97 |
Count On Data Integrity Auditors Making These 10 Requests
|
sureAssist |
2025-01-02 |
319 |
